Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-24
2009-10-20
Minnifield, N. M (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800, C514S800000, C424S184100, C424S193100, C424S198100, C930S020000, C930S110000, C930S130000, C530S300000, C530S313000
Reexamination Certificate
active
07605121
ABSTRACT:
A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.
REFERENCES:
patent: 3816386 (1974-06-01), Hedlund et al.
patent: 4372884 (1983-02-01), Brown et al.
patent: 4504414 (1985-03-01), Folkers et al.
patent: 4512923 (1985-04-01), Flegel et al.
patent: 4565804 (1986-01-01), Rivier et al.
patent: 4693993 (1987-09-01), Stewart et al.
patent: 4701499 (1987-10-01), Kornreich et al.
patent: 4711877 (1987-12-01), Moore
patent: 4716242 (1987-12-01), Engel et al.
patent: 4800191 (1989-01-01), Schally et al.
patent: 4908475 (1990-03-01), Callahan et al.
patent: 5198533 (1993-03-01), Schally et al.
patent: 5204335 (1993-04-01), Sauerbier et al.
patent: 5268360 (1993-12-01), Yashikawa et al.
patent: 5446033 (1995-08-01), Engel et al.
patent: 5663145 (1997-09-01), Engel et al.
patent: 5728738 (1998-03-01), Engel et al.
patent: 5750131 (1998-05-01), Wichert et al.
patent: 5773032 (1998-06-01), Engel et al.
patent: 5945128 (1999-08-01), Deghenghi
patent: 5968895 (1999-10-01), Gefter et al.
patent: 5998377 (1999-12-01), Engel et al.
patent: 6022860 (2000-02-01), Engel et al.
patent: 6054555 (2000-04-01), Engel et al.
patent: 6106805 (2000-08-01), Engel et al.
patent: 6300313 (2001-10-01), Engel et al.
patent: 6319192 (2001-11-01), Engel et al.
patent: 6627609 (2003-09-01), Bernd et al.
patent: 6740634 (2004-05-01), Saikawa et al.
patent: 6780972 (2004-08-01), Damm et al.
patent: 6828415 (2004-12-01), Engel et al.
patent: 6867191 (2005-03-01), Engel et al.
patent: 7005418 (2006-02-01), Riethmuller-Winzen et al.
patent: 7098305 (2006-08-01), Deghenghi et al.
patent: 7148195 (2006-12-01), Bernd et al.
patent: 7214662 (2007-05-01), Sarlikiotis et al.
patent: 7300935 (2007-11-01), Cho et al.
patent: 7388032 (2008-06-01), Saikawa et al.
patent: 7393834 (2008-07-01), Bouchard et al.
patent: 2002/0099018 (2002-07-01), Engel et al.
patent: 2002/0103113 (2002-08-01), Engel et al.
patent: 2002/0198146 (2002-12-01), Damm et al.
patent: 2002/0198186 (2002-12-01), Engel et al.
patent: 2003/0100509 (2003-05-01), Sarlikiotis et al.
patent: 2004/0138138 (2004-07-01), Engel et al.
patent: 2004/0259801 (2004-12-01), Damm et al.
patent: 2004/0266695 (2004-12-01), Bernd et al.
patent: 2005/0032831 (2005-02-01), Kozikowski et al.
patent: 2005/0049200 (2005-03-01), Bouchard et al.
patent: 2005/0124546 (2005-06-01), Engel et al.
patent: 2005/0159335 (2005-07-01), Bauer et al.
patent: 2006/0281685 (2006-12-01), Bernd et al.
patent: 2007/0161571 (2007-07-01), Sarlikiotis et al.
patent: 2007/0196416 (2007-08-01), Li et al.
patent: 2008/0145383 (2008-06-01), Zauner et al.
patent: 2008/0255053 (2008-10-01), Riethmuller-Winzen et al.
patent: 141 996 (1980-06-01), None
patent: 88-308573 (1988-09-01), None
patent: WO 91/19743 (1991-12-01), None
patent: WO 94/13313 (1994-06-01), None
patent: WO 95/15767 (1995-06-01), None
Szende et al, PNAS, USA, Feb. 1990, 87:901-903.
Weinbauer et al, Recent Results in Cancer Research, 1992, 124:113-136.
Bajusz et al, Int. J. Peptide Protein Res., 1988, 32:425-435.
Gonzalez-Barcena et al, the Prostate, 1994, 24:84-92.
Schmidt et al, Contraception, Mar. 1984, 29/3:283-289.
Hahn et al, Life Sciences, 1985, 37/6:505-514.
Bajusz et al, PNAS, USA, Mar. 1998, 85:1637-1641.
Lizio et al, Pharmaceutical Research, 2001, 18/6:771-779.
Seelig et al, Fertility and Sterility, Mar. 2002, 77/3:472-475.
Reissmann et al, European J. Cancer, 1996, 32A/9:1574-1579.
Lizio et al, European J. Pharmaceutical Sciences, 2001, 9:253-258.
Riethmuller-Winzen et al, International J. Gynecology & Obsterics, 2000, 70/Suppl. 1:A97, Abstract # P1.06.19.
Ludwig et al Eur. J. Obst. & Gyn. and Reprod. Biology, 2000, 89:177-179.
Grundker et al, Gynecologic Oncology, 2000, 78:194-202.
Soderhall et al, BBRC, 2005, 333:568-582.
Grohganz et al, Eur. J. Pharmaceutics and Biopharmaceutics, 2005, 59:439-448.
Verschragen et al, Gynecologic Oncology, 2003, 90:552-559.
Erb et al, Fertility and Sterility, Feb. 2001, 75/2:316-323.
Zijlstra et al, Eur. J. Pharmaceutical Sciences, 2004, 23:139-149.
Olivennes et al, Human Reproduction, 1995, 10/6:1382-1386.
Srkalovic et al, Endocrinology, 1990, 127/6:3052-3060.
Behre et al, Clinical Endocriniolgy, 1994, 40:241-248.
Leroy et al, Fertility and Sterility, Sep. 1994, 62/3:461-467.
Norman, Current Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs, 2000, 2/2:227-248.
Albano et al., “The Luteal Phase of Nonsupplemented Cycles After Ovarian Superovulation With Human Menopausal Gonadotropin and the Gonadotropin-Releasing Hormone Antagonist Cetrorelix,”Fertility and Sterility, vol. 70, No. 2, Aug. 1998, pp. 357-359.
Albano et al., “Ovarian Stimulation With HMG: Results of a Prospective Randomized Phase III European Study Comparing the Luteinizing Hormone-Releasing Hormone (LHRH)-Antagonist Cetrorelix and the LHRH-Agonist Buserelin,”Human Reproduction, vol. 15, No. 3, 2000, pp. 526-531.
Albano et al., “Hormonal Profile During the Follicular Phase in Cycles Stimulated with a Combination of Human Menopausal Gonadotrophin and Gonadotrophin-Releasing Hormone Antagonist (Cetrorelix),”Human Reproduction, vol. 11, No. 10, 1996, pp. 2114-2118.
Craft et al., “Will GnRH Antagonists Provide New Hope For Patients Considered ‘Difficult Responders’ to GnRH Agonist Protocols?,”Human Reproduction, vol. 14, No. 12, 1999, pp. 2959-2962.
Christin-Maltre et al., “Effect of Gonadotrophin-Releasing Hormone (GnRH) Antagonist During the LH Surge in Normal Women and During Controlled Ovarian Hyperstimulation,” Clinical Endocrinology. vol. 52, 2000, pp. 721-726.
Diedrich et al., Suppression of the Endogenous Luteinizing Hormone Surge by the Gonadotrophin-Releasing Hormone Antagonist Cetrorelix During Ovarian Stimulation,Human Reproduction, vol. 9, No. 5, 1994, pp. 788-791.
Diedrich et al., “The Role of Gonadotropin-ReleasIng Hormone Antagonists in In Vitro Fertilization,”Seminars in Reproductive Medicine, vol. 19, No. 3, 2001, pp. 213-220.
Felberbaum et al., “Ovarian Stimulation for In-Virtro Fertilization/Intracytoplasmic Sperm Injection With Gonadotrophins and Gonadotrophin-Releasing Hormone Analogues: Agonists and Antagonists,” Human Reproduction, vol. 14, Suppl. 1, 1999, pp. 207-221.
Felberbaum et al., “Preserved Pituitary Response Under Ovarian Stimulation with HMG and GnRH Antagonists (Cetrorelix) in Women with Tubal Infertility,”European Journal of Obstetrics&Gynecology and Reproductive Biology, vol. 61, 1995. pp. 151-155.
Felberbaum et al., “Ovarian Stimulation for Assisted Reproduction with HMG and Concomitant Midcycle Administration of the GnRH Antagonist Cetrorelix According to the Multiple Dose Protocol: A Prospective Uncontrolled Phase III Study.”Human Reproduction, vol. 15, No. 5, 2000. pp. 1015-1020.
Fraser at al., “Control of the Preovulatory Luteinizing Hormone Surge by Gonadotropin-Releasing Hormone Antagonists,”Trends Endocrinol Metal, vol. 5, No. 2, 1994, pp. 87-93.
Klingmoller et al., “Hormonal Responses to the New Potent GnRH Antagonist Cetrorelix,”Acta Endocrinologica, No. 128, 1993, pp. 15-18.
Lin et al., “Is There a Difference in the Function of Granulosa-Luteal Cells in Patients Undergoing In-Vitro Fertilization Either With Gonadotrophin-Releasing Hormone Agonist or Gonadotrophin-Releasing Hormone Antagonist?,”Human Reproduction, vol. 14, No. 4, 1999, pp. 885-888.
Ludwig et al., “Health of 227 Children Born After Controlled Ovarian Stimulation for In Vitro Fertilization Using the Luteinizing Hormone-Releasing Hormone Antagonist Cetrorelix,”Fertility and Sterility, vol. 75, No. 1, 2001, pp. 18-22.
Ludwig et al., “Significant Reduction of the Incidence of Ovarian Hyperstimulation Syndrome (OHSS) by Using the LHRH Antagonist Cetrorelix (Cetrotide) in Contolled Ovarian Stimulation for As
Engel Jürgen
Reissmann Thomas
Sauerbier Dieter
Sauerbier, legal representative Gudrun
Wichert Burkhard
AEterna Zentaris GmbH
Minnifield N. M
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Oligopeptide lyophilisate, their preparation and use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligopeptide lyophilisate, their preparation and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligopeptide lyophilisate, their preparation and use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4103226